Dietary Sargassum fusiforme improves memory and reduces amyloid plaque load in an Alzheimer's disease mouse model

Sci Rep. 2019 Mar 20;9(1):4908. doi: 10.1038/s41598-019-41399-4.

Abstract

Activation of liver X receptors (LXRs) by synthetic agonists was found to improve cognition in Alzheimer's disease (AD) mice. However, these LXR agonists induce hypertriglyceridemia and hepatic steatosis, hampering their use in the clinic. We hypothesized that phytosterols as LXR agonists enhance cognition in AD without affecting plasma and hepatic triglycerides. Phytosterols previously reported to activate LXRs were tested in a luciferase-based LXR reporter assay. Using this assay, we found that phytosterols commonly present in a Western type diet in physiological concentrations do not activate LXRs. However, a lipid extract of the 24(S)-Saringosterol-containing seaweed Sargassum fusiforme did potently activate LXRβ. Dietary supplementation of crude Sargassum fusiforme or a Sargassum fusiforme-derived lipid extract to AD mice significantly improved short-term memory and reduced hippocampal Aβ plaque load by 81%. Notably, none of the side effects typically induced by full synthetic LXR agonists were observed. In contrast, administration of the synthetic LXRα activator, AZ876, did not improve cognition and resulted in the accumulation of lipid droplets in the liver. Administration of Sargassum fusiforme-derived 24(S)-Saringosterol to cultured neurons reduced the secretion of Aβ42. Moreover, conditioned medium from 24(S)-Saringosterol-treated astrocytes added to microglia increased phagocytosis of Aβ. Our data show that Sargassum fusiforme improves cognition and alleviates AD pathology. This may be explained at least partly by 24(S)-Saringosterol-mediated LXRβ activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / genetics
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / physiopathology
  • Amyloid beta-Peptides / antagonists & inhibitors
  • Amyloid beta-Peptides / genetics*
  • Amyloid beta-Peptides / metabolism
  • Aniline Compounds / pharmacology
  • Animals
  • Astrocytes / cytology
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Cognition / drug effects
  • Cognition / physiology
  • Culture Media, Conditioned / pharmacology
  • Disease Models, Animal
  • Gene Expression Regulation
  • Genes, Reporter
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Humans
  • Liver X Receptors / agonists
  • Liver X Receptors / genetics*
  • Liver X Receptors / metabolism
  • Luciferases / genetics
  • Luciferases / metabolism
  • Male
  • Memory, Short-Term / drug effects
  • Memory, Short-Term / physiology
  • Mice
  • Mice, Transgenic
  • Microglia / cytology
  • Microglia / drug effects
  • Microglia / metabolism
  • Neuroprotective Agents / isolation & purification
  • Neuroprotective Agents / pharmacology*
  • Peptide Fragments / antagonists & inhibitors
  • Peptide Fragments / genetics*
  • Peptide Fragments / metabolism
  • Plaque, Amyloid / drug therapy*
  • Plaque, Amyloid / genetics
  • Plaque, Amyloid / metabolism
  • Plaque, Amyloid / physiopathology
  • Sargassum / chemistry*
  • Signal Transduction
  • Stigmasterol / analogs & derivatives*
  • Stigmasterol / isolation & purification
  • Stigmasterol / pharmacology
  • Thiazoles / pharmacology

Substances

  • AZ 876
  • Amyloid beta-Peptides
  • Aniline Compounds
  • Culture Media, Conditioned
  • Liver X Receptors
  • Neuroprotective Agents
  • Peptide Fragments
  • Thiazoles
  • amyloid beta-protein (1-42)
  • saringosterol
  • Stigmasterol
  • Luciferases